All In Biotech

NDA 205579 · Eagle Pharms

Ryanodex

Dantrolene Sodium · Intravenous

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jul 22, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

12

4 Phase 3, 1 recruiting

FAERS reports

410

346 serious, 47 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 30, 2024.

RYANODEX ® is indicated for the: Treatment of malignant hyperthermia in conjunction with appropriate supportive measures [see Dosage and Administration ( 2.1 )] Prevention of malignant hyperthermia in patients at high risk. RYANODEX is a skeletal muscle relaxant drug indicated for: Treatment of malignant hyperthermia in conjunction with appropriate supportive measures. ( 1 ) Prevention of malignant hyperthermia in patients at high risk. ( 1 )

Mechanism: In isolated nerve-muscle preparation, dantrolene has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, dantrolene dissociates the excitation-contraction coupling, probably by interfering with the release of Ca ++ from the sarcoplasmic reticulum. In the anesthetic-induced malignant hyperthermia syndrome, evidence points to an intrinsic abnormality of skeletal muscle tissue. In affected humans, it has been postulated that “triggering agents” (e.g., general anesthetics and depolarizing neuromuscular...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • RYANODEX · DANTROLENE SODIUM 250MG/VIAL · FOR SUSPENSION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dantrolene" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neuroleptic malignant syndrome44
  • respiratory failure35
  • drug ineffective31
  • muscular weakness29
  • asthenia28
  • pyrexia28
  • convulsion26
  • diarrhoea26
  • vomiting21
  • fatigue19
  • off label use19
  • pneumonia19

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20059
200618
200728
200829
200927
201015
201137
201216
201310
201411
20158
201619
201718
201823
201919
202021
202116
202218
202324
202413
202516
20267

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 88 on PubMed

Sponsor: Eagle Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.